{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-059557","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.118307+00:00","generated_at":"2026-05-23T04:24:57.123431+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Perspective Therapeutics doses first patient in Phase 1/2a trial of PSV359 for FAP-α positive solid tumors","bullets":["First patient dosed with [212Pb]PSV359 in Phase 1/2a dose-finding trial for FAP-α positive solid tumors.","Patients selected via SPECT imaging with [203Pb]PSV359 to identify FAP-α expression.","Trial aims to determine safety and preliminary anti-tumor activity; dose selection for monotherapy or combination.","PSV359 construct optimized for tumor uptake, retention, and fast clearance from healthy tissues."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-059557","json":"https://secwatch.observer/filing/0000950170-25-059557.json","markdown":"https://secwatch.observer/filing/0000950170-25-059557.md","text":"https://secwatch.observer/filing/0000950170-25-059557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025059557/0000950170-25-059557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025059557/catx-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:24:57.123431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}